Lidocaine Administration
PreclinicalSmall molecule
Lidocaine Administration is one of 27 small molecule programs targeting Pancreatitis. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Pancreatitis
#DrugCompanyPhaseTrials
1Indocin
CCosette Pharmaceuticals, Inc.
Approved
Voltaren
NovartisApproved
Cysteine Hydrochloride
NovartisApproved
Doribax
ShionogiApproved
Avycaz
PPhiladelphia Eye Associates
Approved
Nitrostat
VViatris Specialty LLC
Approved
Imuran
LLegacy Health System
Approved
Chantix
PPrism Pharmaceuticals
Approved
Trental
VValidus Pharmaceuticals
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lidocaine Administration. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNorthwestern University